Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

GREY:CLAZF - Post Discussion

Claritas Pharmaceuticals Inc > material change
View:
Post by monkey245 on Feb 18, 2021 5:04pm

material change

Kalytera Therapeutics, Inc. MATERIAL CHANGE REPORT Item 1: Name and Address of Company Kalytera Therapeutics, Inc. (the “Company” or “Kalytera”) 4040 Civic Center Drive Suite 200 San Rafael, California, USA, 94903 Item 2: Date of Material Change January 22, 2021 Item 3: News Release A news release was issued and disseminated through the facilities of Baystreet and Stockwatch on January 22, 2021, and filed on SEDAR (www.sedar.com). A copy of the news release is attached as Schedule “A” hereto. Item 4: Summary of Material Change On January 22, 2021 the Company’s previously announced FFCTO was fully revoked by the British Columbia Securities Commission and the Ontario Securities Commission. The Company is following up with the TSXV to remove its suspension and resume the trading of the Company’s common shares, which resumption when effected will be confirmed in a follow up press release. The Company confirms that its business has not changed, the Company remains active, and there are no changes to its current business plans. Readers are urged to review the attached news release at Schedule "A" to this report for complete details on the above mentioned matters. Item 5: Full Description of Material Change See attached news release at Schedule "A" to this report. Item 6: Reliance on Subsection 7.1(2) of National Instrument 51-102 Not applicable. Item 7: Omitted Information Not applicable. Item 8: Executive Officer The following executi
Comment by Captainblk on Feb 18, 2021 5:52pm
why were we posting this document from a month ago?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities